Patrick Campbell is the managing editor of HCPLive. Formerly the editorial lead of Endocrinology Network, Practical Cardiology, and Rheumatology Network, Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. He now helps to lead coverage in each of these respective areas for HCPLive. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter with the Pocono Record in Stroudsburg, PA, and Star News Group in Manasquan, NJ. He also touts experience in multimedia, having spent time as a multimedia specialist with NJ Advance Media and multimedia coordinator at the Pocono Record. Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.
SGLT2 Inhibitors Could Lower Risk of Recurrent Gout Flares in People with Diabetes
June 4th 2023A new-user, active comparator cohort study from EULAR 2023 suggests use of SGLT2 inhibitors could lower risk of recurrent gout flares in people with type 2 diabetes and gout compared to use of DPP-4 inhibitors.
Read More
Depressive Symptoms During Pregnancy, Postpartum Depression Common in Women with Rheumatic Disease
June 4th 2023A pair of studies presented at EULAR 2023 offer perspective on the potential for postpartum depression as well as symptoms of depression and anxiety during pregnancy among women with rheumatic disease.
Read More
Even With High Proteinuria, Voclosporin Proves Benefit in Lupus Nephritis
June 4th 2023An analysis of data from the phase 2 AURA-LV and phase 3 AURORA 1 trials provides new insight into the effects of voclosporin for the treatment of active lupus nephritis in patients with high proteinuria.
Read More
Pegloticase Use Could Contribute to Bone Remodeling in Gout Patients
June 2nd 2023An analysis of DECT imaging from the MIRROR trial is providing clinicians with insight into the potential for urate crystal resolution and bone remodeling with pegloticase plus methotrexate in patients with uncontrolled gout.
Read More
For People with Diabetes, Starting an SGLT2 Inhibitor Could Lower Gout Risk
June 2nd 2023An analysis of more than 20,000 people with type 2 diabetes suggests initiating therapy with an SGLT2 inhibitor, as a second-line treatment to metformin, was associated with a lower risk of developing gout relative to other second-line therapies.
Read More
Pegloticase Use and Quality of Life in Uncontrolled Gout, with Brian LaMoreaux, MD
June 1st 2023Brian LaMoreaux, MD, discusses data from an analysis of the MIRROR trial examining the impact of pegloticase plus methotrexate on patient-reported outcomes and quality of life measures among patients with uncontrolled gout.
Read More
Risankizumab Provides Durable Quality of Life Improvements out to 100 Weeks in Psoriatic Arthritis
June 1st 2023An analysis of 100 week data from the KEEPsAKE 1 and 2 trials presented at EULAR 2023 offers insight into the long-term effects of risankizumab use in people with psoriatic arthritis.
Read More
Achieving Remission with Methotrexate or TNFi Linked to Lower CV Risk in Rheumatoid Arthritis
May 31st 2023An analysis of patient data from Sweden and Norway detail the impact of achieving remission with methotrexate or TNF inhibitors on risk of acute coronary syndrome in patients with rheumatoid arthritis.
Read More
BE VITAL: Bimekizumab Helps Control, Attenuate Disease Activity in Psoriatic Arthritis
May 31st 2023Data from the BE VITAL OLE study, which included patients from the BE COMPLETE and BE OPTIMAL studies, suggests the benefits of bimekizumab in patients with psoriatic arthritis with inadequate response or intolerance to TNF inhibitors were sustained for up to 52 weeis.
Read More
Study Warns of Potential for Hastened Cognitive Decline Following Heart Attacks
May 30th 2023Pooling data from half a dozen major population-based cohort studies, a Johns Hopkins-led team provides new insight into the risk of cognitive decline following myocardial infarction among US adults.
Read More
Bariatric, Metabolic Procedures on the Rise in US Youth and Adolescents
May 30th 2023An analysis of data from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program provides an overview of changing rates of access and utilization of metabolic and bariatric surgery among US youths.
Read More
FINEARTS-HF Baseline Data Offer Insight into Historic Trial, with Scott Solomon, MD
May 29th 2023Scott Solomon, MD, of Brigham and Women's Hospital, discusses how baseline patient characteristics inform what cardiologists might learn from the FINEARTS-HF trial, which he presented at Heart Failure 2023.
Read More
Exploring the Impact of the Sotagliflozin Approval, with Deepak Bhatt, MD, MPH
May 27th 2023Ahead of the sotagliflozin approval, Deepak Bhatt, MD, MPH, offers perspective into potential future research opportunities for the SGLT1/2 inhibitor and discusses the impact of a 3rd agent boasting SGLT2 inhibition receiving approval for heart failure.
Read More
ELAN Trial: Early Initiation of DOACs Reduces Event Risk after Stroke Event
May 24th 2023Presented at the European Stroke Conference, results of the ELAN trial offer evidence in support of early initiation, as opposed to later initiation, strategies for anticoagulation following acute ischemic stroke in patients with atrial fibrillation.
Read More
Study Finds FRAX Score Could Be Missing the Mark for Women in the US
May 23rd 2023An analysis of data from more than 60,000 postmenopausal women within the Women's Health Initiative has returned results indicating the guideline-recommended FRAX score may be insufficient for making screening decisions.
Read More